12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AR-12286: Phase IIa data

Top-line data from a double-blind, U.S. Phase IIa trial in 93 patients with primary open-angle glaucoma or ocular hypertension showed that a fixed combination of once-daily 0.5% AR-12286 plus travoprost met the primary endpoint of reducing IOP from baseline to day 7 vs. travoprost...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >